"NovoSorb BTM is delivering outstanding clinical results with leading US, New Zealand and Australian surgeons now using the device regularly and several surgeons stating they no longer use biologic based scaffolds. "
"NovoSorb BTM is becoming the standard dermal scaffold of choice in some hospitals with the word spreading that it is outperforming the established biological based products."
- Looks like NovoSorb is quickly becoming the standard of care. Why would you use anything else?
Ann: Annual Report FY19 and 4E, page-32
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.35 |
Change
-0.060(2.49%) |
Mkt cap ! $1.625B | |||
| Open | High | Low | Value | Volume |
| $2.43 | $2.43 | $2.34 | $1.080M | 454.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 14356 | $2.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.36 | 25600 | 33 |
View Market Depth
| Last trade - 11.05am 25/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |